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Background: The molecular mecha-
nisms underlying the progression of
prostate cancer during hormonal
therapy have remained poorly under-
stood. In this study, we developed a
new strategy for the identification of
differentially expressed genes in hor-
mone-refractory human prostate can-
cer by use of a combination of comple-
mentary DNA (cDNA) and tissue
microarray technologies. Methods: Dif-
ferences in gene expression between
hormone-refractory CWR22R prostate
cancer xenografts (human prostate
cancer transplanted into nude mice)
and a xenograft of the parental, hor-
mone-sensitive CWR22 strain were
analyzed by use of cDNA microarray
technology. To validate the data from
cDNA microarrays on clinical prostate
cancer specimens, a tissue microarray
of specimens from 26 prostates with
benign prostatic hyperplasia, 208 pri-
mary prostate cancers, and 30 hor-
mone-refractory local recurrences was
constructed and used for immuno-
histochemical detection of protein ex-
pression. Results: Among 5184 genes
surveyed with cDNA microarray tech-
nology, expression of 37 (0.7%) was
increased more than twofold in the
hormone-refractory CWR22R xeno-
grafts compared with the CWR22 xe-
nograft; expression of 135 (2.6%) genes
was reduced by more than 50%. The
genes encoding insulin-like growth
factor-binding protein 2 (IGFBP2)
and 27-kd heat-shock protein (HSP27)
were among the most consistently over-
expressed genes in the CWR22R tu-
mors. Immunohistochemical analysis
of tissue microarrays demonstrated
high expression of IGFBP2 protein in
100% of the hormone-refractory clini-
cal tumors, in 36% of the primary
tumors, and in 0% of the benign pros-
tatic specimens (two-sided P = .0001).
Overexpression of HSP27 protein was
demonstrated in 31% of the hormone-
refractory tumors, in 5% of the pri-
mary tumors, and in 0% of the benign
prostatic specimens (two-sided P =
.0001). Conclusions: The combination
of cDNA and tissue microarray tech-
nologies enables rapid identification
of genes associated with progression
of prostate cancer to the hormone-
refractory state and may facilitate
analysis of the role of the encoded gene
products in the pathogenesis of human
prostate cancer. [J Natl Cancer Inst
1999;91:1758–64]
Despite the widespread use of prostate-
specific antigen screening for early detec-
tion, prostate cancer remains the second
leading cause of cancer-related death
among men in western countries (1).
Metastatic, hormone-refractory prostate
cancer is the end-stage, lethal form of the
disease. Defining the molecular mecha-
nisms underlying the transition of an an-
drogen-responsive prostate cancer to a
hormone-refractory prostate cancer repre-
sents both an intriguing biologic question
and a critical clinical problem (2). It is
important to better understand the bio-
logic basis of prostate cancer progression,
since no effective therapies exist for end-
stage, hormone-refractory disease.
There are several in vitro and in vivo
models for the study of hormone-
refractory prostate cancer. For example,
numerous hormone-independent strains
of the LNCaP human prostate cancer cell
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line have been developed (3). Several hor-
mone-refractory xenograft model systems
also exist. Human xenografts are con-
structed by the introduction of human
prostate tissue or cells into immunodefi-
cient mice where they can be serially
transplanted. For example, the CWR22
xenograft tumor grows in nude mice and
recurs as hormone-refractory disease after
castration of the mice (4). The availability
of such model systems will become in-
creasingly powerful, as high-throughput
genomic technologies, such as large-scale
parallel gene expression analysis with
complementary DNA (cDNA) microar-
rays or serial analysis of gene expression
(5,6), become more widely available. The
quantity of information obtained from
the analysis of the expression of thou-
sands of genes at once creates unique
opportunities for research but also poses
substantial challenges. For example,
which of the hundreds of differentially
expressed genes identified in large-scale
gene expression surveys are important
primary events and which are down-
stream or secondary changes? Further-
more, are novel genes discovered from
experimental model systems of cancer
progression also involved in the cancer
progression of human patients? By use of
traditional methods in molecular pathol-
ogy, substantial work is required to ana-
lyze the frequency of involvement or the
clinical significance of just a single gene
or protein. We recently developed a tissue
microarray-based technology for high-
throughput molecular analyses of human
cancer (7). This tumor tissue microarray
(“tissue chip”) technique is based on the
arraying of cylindrical biopsy specimens
from hundreds of different tumors into a
single paraffin block. Consecutive sec-
tions of this tissue microarray block can
then be used for the analysis of multiple
molecular alterations at the DNA, RNA,
and protein levels in hundreds of tumors
per experiment.
In this study, we combined the cDNA
and tissue microarray technologies to
identify molecular alterations associated
with the progression of human prostate
cancer. First, the CWR22/CWR22R hu-
man prostate cancer xenograft model (4)
was used to screen for differential mes-
senger RNA (mRNA) expression of more
than 5000 genes between hormone-
refractory and hormone-responsive pros-
tate cancers. Two consistently overex-
pressed genes, insulin-like growth factor-
binding protein 2 (IGFBP2) and the 27-kd
heat-shock protein (HSP27), were then
validated to be involved in clinical pros-
tate cancer progression on the basis of im-
munohistochemical analysis of the en-
coded proteins in a prostate cancer tissue
microarray containing 264 clinical speci-
mens from various stages of tumor pro-
gression.
MATERIALS AND METHODS
Xenograft tumors. CWR22 is a serially trans-
plantable, human prostate cancer that was derived
from a Gleason score 9 primary prostate cancer with
osseous metastasis (8). CWR22 is highly responsive
to androgen deprivation, with marked tumor regres-
sion after castration (4). About half of the treated
animals develop recurrent tumors (CWR22R) over a
time from a few weeks to several months. CWR22R
is not dependent on androgen and is able to grow in
castrated animals (4). Nude mice were housed and
cared for as described earlier (8,9). Their care was in
accord with institutional guidelines. Fresh-frozen
human prostate xenograft tissues (one sample from
CWR22 and four independent hormone-refractory
CWR22R strains) were obtained.
Comparative genomic hybridization. Compara-
tive genomic hybridization was used to characterize
the tumor progression in this model system and was
carried out essentially as described previously (10),
with some modifications. In brief, tumor (test) and
normal male (reference) DNAs were labeled by nick
translation incorporating either SpectrumGreen or
SpectrumRed deoxyuridine diphosphates (Vysis
Inc., Downers Grove, IL). Labeled DNAs were hy-
bridized to denatured normal peripheral blood met-
aphase slides. After acquisition of digital images on
wavelengths matching the 48 ,6-diamidino-
phenylindole, SpectrumGreen and SpectrumRed
emissions, green-to-red-ratio profiles were quanti-
tated with Quips XL program (Vysis Inc.). Green
and red intensities were normalized so that the av-
erage green-to-red ratio in each metaphase was set to
1.0. Chromosomal regions where ratios exceeded
1.2 were considered as gained, and those regions
where the ratio was less than 0.8 was considered as
lost.
cDNA microarrays. RNA was prepared from
CWR22/CWR22R xenografts as described by Chir-
gwin et al. (11), with minor modifications. mRNA
was purified with the use of oligo(dT) selection with
DynaBeads (Dynamic Analysis Inc., Huntsville,
AL) according to the manufacturer’s instructions.
Two different cDNA microarray formats were used
(Clontech Laboratories, Inc. [Palo Alto, CA], and
Research Genetics, Inc. [Huntsville, AL]). The Atlas
human cDNA expression array from Clontech Labo-
ratories, Inc. contains 588 duplicate spots on a single
membrane, each representing 8–10 ng of cDNA of
known and sequence-verified genes. These arrays
were hybridized with [32P]deoxycytidine triphos-
phate (dCTP)-labeled cDNA probes prepared from 2
mg of polyadenylic acid–RNA. In addition, we used
cDNA array filters from Research Genetics, Inc.
(Prostate array, version I), with transcripts known to
be expressed in the prostate on the basis of ex-
pressed sequence tag (EST) sequences found in nor-
mal or malignant cDNA libraries. These filters con-
tained 5184 spots (each with 5 ng of cDNA) of
known genes (n 4 1960) or expressed sequence tags
(ESTs; n 4 3224), which were not sequence veri-
fied. These arrays were hybridized with [33P]dCTP-
labeled cDNAs derived from 50 mg of total RNA.
After overnight hybridization at 68 °C in Ex-
pressHyb solution (Clontech Laboratories, Inc.), the
filters were washed and exposed to a high-resolution
screen (Molecular Dynamics, Sunnyvale, CA) for 3
days and scanned on a Storm PhosphorImager®
(Molecular Dynamics). The spot intensities reflect-
ing gene expression levels on the Atlas human
cDNA array filter were quantified with Image-
Quant® software (Molecular Dynamics), and those
on the Research Genetics prostate-specific filter
were quantified with a custom software (Dearray
software: Y. Chen). The normalization of the spot
intensities within an experiment (CWR22R versus
CWR22) was done on the basis of the average of the
intensities of all spots. The gene expression profiles
of the CWR22Rs were compared with the gene ex-
pression profile of CWR22. To define genes/ESTs
as underexpressed or overexpressed, an at least two-
fold expression difference was required. In addition,
visual confirmation of all differentially expressed
spots on filters was performed. The gray-scale im-
ages were pseudocolored (red for hormone refrac-
tory and green for hormone responsive) and overlaid
for better visualization of the relative expression in-
tensities with Adobe Photoshop software (Adobe
Systems Inc., San Jose, CA).
Reverse transcription–polymerase chain reac-
tion (RT–PCR). cDNA was prepared by reverse
transcriptase reaction by use of oligo(dT) primer
(Research Genetics, Inc.). PCR was carried out with
specific primers for the IGFBP2 (Gene Bank
#M35410) and HSP27 gene (Gene Bank #M54079)
at an annealing temperature of 55 °C for 27 cycles
generating 391-base-pair (bp) and 260-bp products,
respectively. Aliquots of the reaction products were
subjected to electrophoresis on a 2% agarose gel and
visualized by staining with ethidium bromide. Am-
plification of the human asparagine synthetase gene
by use of specific primers was used as a control.
Prostate tissue microarray. Formalin-fixed and
paraffin-embedded tumor and benign control speci-
mens were obtained from the archives of the Insti-
tutes for Pathology, University of Basel (Switzer-
land) and the Tampere University Hospital
(Finland). All sections of tumors and controls were
reviewed by one pathologist (L. Bubendorf). Tumor
grading was performed according to the method of
Gleason (12). The specimens included 208 primary
prostate cancers, 30 transurethral resection speci-
mens from locally recurrent hormone-refractory
cancers operated on from 1976 through 1997, and 26
transurethral resections for benign prostatic hyper-
plasia as benign controls. The group of primary
(non-hormone-refractory) prostate cancers consisted
of 56 incidentally detected tumors in transurethral
resections for presumed benign prostatic hyperplasia
(stage T1a or b), 137 radical prostatectomy speci-
mens from patients with clinically localized disease
(stage T2), and specimens from 15 patients with
locally extensive disease (stage T3 or T4) (13). More
than one sample per tumor specimen was arrayed in
34 of the 238 patients. In these cases, the sample
with the strongest immunohistochemical staining
was chosen for the immunohistochemical classifica-
tion. The array also included 114 autopsy specimens
from hormone-refractory metastatic prostate can-
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cers. These were excluded from this analysis, since
immunohistochemistry is often unreliable in tissues
from routine autopsies because of protein degrada-
tion. The prostate tissue microarray was constructed
as previously described (7). In brief, core tissue bi-
opsy specimens (diameter, 0.6 mm) were taken from
the least differentiated regions of individual paraf-
fin-embedded prostate tumors (donor blocks) and
precisely arrayed into a new recipient paraffin block
(35 × 20 mm) with a custom-built precision instru-
ment (Beecher Instruments, Silver Spring, MD). Af-
ter the block construction was completed, 5-mm sec-
tions were cut with a microtome by use of an
adhesive-coated tape sectioning system (Instrumed-
ics, Hackensack, NJ) to support the adhesion of the
array elements. The presence of tumor tissue on the
arrayed samples was verified on an hematoxylin–
eosin-stained section.
Immunohistochemistry. Antigen retrieval was
performed by treatment in a pressure cooker for 5
minutes. Standard indirect immunoperoxidase pro-
cedures were used for immunohistochemistry
(ABC-Elite; Vector Laboratories, Inc., Burlingame,
CA). A goat polyclonal antibody, C-18 (1 : 1000;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
was used for detection of IGFBP2. HSP27 protein
was detected by use of a monoclonal mouse anti-
body HSP27 (1 : 100; BioGenex Laboratories, San
Ramon, CA). The reactions were visualized by di-
aminobenzidine as a chromogen. The primary anti-
bodies were omitted for negative staining controls.
The intensity of the cytoplasmic IGFBP2 and
HSP27 staining was classified into four groups
(negative, weak, intermediate, and strong staining).
The number of tumors that could be analyzed for
IGFBP2 and HSP27 expression differed slightly
from each other because of loss of representative
prostate cancer tissue on consecutive sections of
some punch samples.
Statistical analysis. Contingency table analysis
was used to analyze the relationship between immu-
nohistochemical staining, grade, and stage (total chi-
squared test). All P values were two-sided.
RESULTS
Analysis of Chromosomal Alterations
by Comparative Genomic
Hybridization
The hormone-sensitive CWR22 xeno-
graft contained five chromosomal aberra-
tions, including gain of 1q, gain of whole
chromosomes 7, 8, and 12, and loss of 2q.
The same five aberrations were also pre-
sent in the hormone-refractory CWR22R
xenograft, indicating that the recurrent tu-
mor was a clonal derivative of the pri-
mary CWR22. In addition, the CWR22R
showed a gain of chromosome 14q, which
was not present in the primary CWR22
(data not shown).
cDNA Microarray Analysis of Gene
Expression Changes
cDNA microarray experiments were
first performed with a nylon filter-based
588 clone array (Clontech Laboratories,
Inc.). This analysis revealed 10 overex-
pressed and 14 underexpressed genes in at
least two or more of the four hormone-
refractory CWR22R xenografts as com-
pared with the hormone-responsive
CWR22 xenograft (Table 1). Among
these, HSP27 was substantially overex-
pressed in three of the four CWR22R
strains (median ratio, 2.6) and IGFBP2
in all four CWR22Rs (median ratio,
2.6). Two other members of the insulin-
like growth factor (IGF) pathway—
insulin-receptor and IGF-II—were also
markedly overexpressed in two of the
four CWR22R xenografts. RT–PCR
analysis confirmed the finding that the ex-
pression of IGFBP2 and HSP27 was in-
creased in hormone-refractory CWR22R
strains as compared with hormone-
sensitive CWR22 strains (Fig. 1).
In addition to these consistently differ-
entially regulated genes in two or more
xenograft specimens, 47 genes were over-
expressed and 89 genes were underex-
pressed in only one of the four hormone-
refractory CWR22R xenografts.
To further explore the differential gene
expression patterns in hormone-refractory
prostate cancer, we analyzed the same tu-
mors with a much larger cDNA microar-
ray (5184 spots, Research Genetics, Inc.)
containing a comprehensive collection of
genes and ESTs found to be expressed in
Table 1. Most consistently overexpressed and underexpressed genes in the complementary
DNA microarray experiments and the ratios of gene expression in hormone-refractory human prostate















IGFBP2 2q33–q34 2.7 2.4 2.6 5.3 2.6
Heat-shock 27-kd protein 7q 2.6 2.7 1.5 4.8 2.6
Insulin receptor 19p13.3–p13.2 1.8 1.5 2.9 5.3 2.4
Transcription factor LCR-F1 7q32 3.2 3.1 0.8 0.9 2.0
BSP-1 4q28 2.8 2.9 1.1 1.1 2.0
P14-cyclin dependent kinase
inhibitor
9p21 2.4 2.7 1.2 1.3 1.9
Insulin-like growth factor-II 11p15.5 1.1 0.7 2.7 2.1 1.6
Homeobox protein HOX-A4 7p15–p14 2.0 2.1 1.2 1.1 1.6
Tumor suppressor protein DCC 18q21.1 2.2 2.6 0.7 0.7 1.5
ETS variant gene 3 1q21–q23 2.1 2.1 0.9 0.9 1.5
Underexpressed
Oncostatin M 22q12.1–q12.2 0.2 0.3 1.1 0.5 0.4
Integrin alpha 2B 17q21.32 0.5 0.3 1.4 0.2 0.4
T-lymphocyte-secreted
protein I-309
17 0.3 0.6 0.7 0.5 0.5
CD40 ligand Xq26 0.4 0.6 0.8 0.3 0.5
Acyl-COA-binding protein 2q12–q21 0.4 1.2 0.5 0.4 0.5
Interleukin 9 receptor Xq28 or Yq12 0.4 0.4 0.8 0.6 0.5
E-selectin 1q22–q25 0.8 0.6 0.3 0.4 0.5
Fms-like tyrosine kinase 4 5q34–q35 0.3 0.7 0.5 0.4 0.6
Interleukin 2 receptor alpha chain 10p15–p14 0.4 0.5 1.1 1.3 0.8
Hepatoma-derived growth factor Xq25 0.4 0.5 1.0 1.8 0.8
Interleukin 7 receptor alpha chain 5p13 0.4 0.5 1.0 1.9 0.8
Cyclin H 5q13.3–q14 1.0 1.7 0.5 0.3 0.8
SHB adaptor protein 9p12–p11 1.4 1.7 0.5 0.5 1.0
Clusterin 8p21–p12 0.4 0.3 2.0 2.0 1.2
*IGFBP2 4 insulin-like growth factor-binding protein 2; LCR-F1 4 locus control region F1; BSP-1 4
transforming growth factor-b signaling protein-1; DCC 4 deleted in colorectal carcinoma; ETS 4 E-
twenty-six specific; SHB 4 src homology B.
Fig. 1. Reverse transcription–polymerase chain re-
action analysis of insulin-like growth factor-binding
protein 2 (IGFBP2), 27-kd heat-shock protein
(HSP27), and asparagine synthetase (internal con-
trol) expression in one hormone-responsive
(CWR22) and in four hormone-refractory prostate
cancer xenografts (CWR22Ra–d).
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cDNA libraries from normal or malignant
prostate. Altogether, 172 overexpressed
or underexpressed genes or ESTs (ap-
proximately 3%) in at least three of the
four hormone-refractory derivatives were
discovered as compared with the un-
treated, hormone-sensitive human pros-
tate cancer xenograft. Thirty-seven tran-
scripts (0.7%) were substantially (ratio
>2) elevated and 135 (2.6%) were under-
expressed (ratio <0.5) in the CWR22R xe-
nografts. A pseudocolored overlay of one
CWR22/CWR22R comparison and the
corresponding ratio distribution are
shown in Fig. 2.
Histology and Immunohistochemistry
To evaluate whether the gene expres-
sion changes seen in the hormone-
refractory CWR22R tumors reflected
molecular changes involved in tumor pro-
gression in patients with prostate cancer,
we created a tissue microarray to analyze
the expression of two overexpressed
genes, IGFBP2 and HSP27, at the protein
level in 238 different human prostate can-
cers and in 26 benign prostate tissues. The
total number of evaluable specimens
on the tissue microarray was 264 for the
IGFBP2 and 258 for the HSP27 immuno-
staining.
In these arrayed clinical specimens, a
strong association was seen between in-
creased IGFBP2 and HSP27 protein ex-
pression and the progression of prostate
cancer to hormone-refractory disease
(Fig. 3). A strong cytoplasmic IGFBP2
staining was present in all of the 30 lo-
cally recurrent, hormone-refractory pros-
tate cancers, in 74 (36%) of the 208
primary tumors, and in none of the 26
benign prostate specimens (Fig. 3; P 4
.0001, two-sided). HSP27 was strongly
expressed in nine (31%) of 29 recur-
rent tumors, in 11 (5%) of 204 primary
tumors, but never in the secretory pros-
tate epithelial cells of 25 benign pros-
tatic hyperplasia specimens (Fig. 3; P 4
.0001, two-sided). There was no statisti-
cally significant association between IG-
FBP2 or HSP27 expression and tumor
grade or T stage in the primary tumors
(data not shown). A subgroup of 36
patients had received primary neoadju-
vant endocrine therapy before radical
prostatectomy, but their IGFBP2 and
HSP27 expression data were similar to
those of the untreated patients (data not
shown).
DISCUSSION
The transition from a hormone-
sensitive human prostate cancer to a hor-
mone-refractory recurrent strain in the
CWR22 xenograft model system re-
sembles the clinical progression of human
prostate cancer (4). As shown in this
study by comparative genomic hybridiza-
tion, there was a close clonal genetic re-
lationship between the primary and recur-
rent xenograft tumors. Furthermore, many
of the alterations seen by comparative ge-
nomic hybridization in this model system,
such as gains of chromosome 7 and 8, are
similar to those commonly found in clini-
cal specimens from patients with prostate
cancer. The cDNA microarray technology
allows rapid, large-scale screening of ex-
pression of hundreds or thousands of
genes in a single experiment (5). Here, up
to 170 genes (3.3%) were identified to be
differentially expressed between the pri-
mary and recurrent (hormone-sensitive
and hormone-refractory) xenograft tu-
mors. This high number of differentially
expressed genes illustrates the complex
molecular basis of prostate cancer pro-
gression. The regrowth of the hormone-
refractory tumor during androgen depri-
vation therapy may necessitate a complex
reprogramming of multiple key regula-
tory mechanisms involving cell growth,
apoptosis (i.e., programmed cell death),
and other signaling pathways. It will be
important to identify the molecular
mechanisms that contribute to the devel-
opment of recurrent tumors and to exam-
ine if some of the signaling pathways in-
volved would provide starting points for
the development of novel diagnostic or
therapeutic approaches for patients with
advanced, hormone-refractory prostate
cancers.
The translation of gene-expression
findings from model systems to human
patients with cancer presents several chal-
lenges. First, although this xenograft
model system displayed phenotypic prop-
erties resembling human prostate cancer
progression, it remains important to vali-
date whether the same alterations of gene
expression and the same signaling path-
ways contribute to the disease progression
in human cancer patients. Second, to uti-
lize the cDNA microarray data for the de-
velopment of improved diagnostic or
therapeutic approaches, it remains criti-
cally important not only to screen for ex-
pression of many different genes but also
to screen many different tumor tissues
and establish an accurate frequency of in-
Fig. 2. Hybridization of the pros-
tate complementary DNA microar-
ray containing 5184 genes (Re-
search Genetics, Inc.). A color
image overlay of the CWR22 hy-
bridization (green) and CWR22R
recurrent xenograft (red) is shown.
Spots with more red color repre-
sent transcripts overexpressed in
the hormone-refractory tumor in
comparison to the primary tumor,
yellow spots indicate genes that
were equally abundant, and green
spots indicate underexpressed
genes in CWR22R. Genes that
were not expressed in either of the
two tissues appear in the black
background color. Inset (histo-
gram) shows a normal frequency
distribution of the log10 intensity
ra t ios for CWR22R versus
CWR22 for all of the 5184 spots
on the microarray. The ratios are
displayed on the x-axis, and the
relative frequency of genes with
the given ratios is indicated on the
y-axis. Ratios of genes that have a
twofold or higher expression in the
recurrent than in the primary xeno-
graft tumor are shown as red bars
and those with a 50% or more re-
duction as green bars.
Journal of the National Cancer Institute, Vol. 91, No. 20, October 20, 1999 REPORTS 1761
volvement of these genes in different
stages of the prostate cancer progression.
A substantial amount of work is required
to fully explore the role of just a single
gene in cancer. Before performing full-
length cDNA cloning, functional analy-
ses, and other tedious experiments, one
would have to prioritize the long list of
potential target genes that always emerges
from cDNA microarray experiments and
to perform large-scale studies of clinical
specimens. In this study, we first took ad-
vantage of the fact that the pattern of gene
expression in the recurrent xenograft tu-
mors was different from one animal to
another. Therefore, we decided to first
concentrate on those genes that were dif-
ferentially expressed in two or more re-
current xenograft tissues. One would ex-
pect that such genes are more likely to be
associated with hormone therapy failure,
whereas genes that are only overex-
pressed in one case may be important
only for that particular tumor. The deci-
sive step was the evaluation of gene ex-
pression patterns in clinical specimens by
use of our newly developed tissue micro-
array technology.
Evaluation of all candidate genes
emerging from the present cDNA micro-
array experiments in a large series of un-
cultured clinical tumors would take years
if traditional methods were used. Further-
more, after a few hundred genes had been
analyzed, one would run out of the avail-
able tumor tissues. Tissue microarray
technology substantially facilitates the
translation of basic research findings to
clinical applications (7) and makes it pos-
sible to perform in situ analysis of hun-
dreds of tumors either at the DNA, the
RNA, or the protein level. This study was
done with immunocytochemical tech-
niques, but expression analyses of newly
identified genes could also be analyzed by
mRNA in situ hybridization when anti-
bodies are not available. Such a strategy
allows one to quickly validate and further
explore in a large number of clinical
specimens the in vivo significance of can-
didate genes discovered with the cDNA
microarrays. Only minute amounts of tis-
sues are required to make the tissue mi-
croarray blocks, causing minimal damage
to the original tumor blocks. Since one
can generate multiple replicate tissue mi-
croarray blocks, each of which can be sec-
tioned 200–300 times, one could easily
generate thousands of tissue microarray
sections from the same set of clinical tu-
mor material. Each section can be utilized
for the analysis of a different molecular
marker.
The small size of the samples makes
tissue microarrays a powerful screening
tool. However, the small tissue samples
may not always be representative of the
whole tumor and, therefore, the preva-
lence of a molecular alteration in a tissue
microarray analysis may be underesti-
mated. However, sampling bias may not
be a serious concern if the tumor areas are
carefully selected for punching. In our
previous studies (7,14), we found a high
concordance between gene-amplification
frequencies on tissue microarrays when
compared with the data from the litera-
ture. The representativeness of tissue mi-
croarray data could be improved by in-
Fig. 3. A) Hematoxylin–eosin and immunohistochemical staining of insulin-like growth factor-binding
protein 2 (IGFBP2) and 27-kd heat-shock protein (HSP27) on the prostate cancer tissue microarray (original
magnification ×200). Benign prostate glands show no immunoreactivity. Primary untreated prostate cancer
(PRCA) demonstrates weak immunostaining of IGFBP2 but no immunoreactivity of HSP27. In contrast,
hormone-refractory prostate cancer with local recurrence (Hr PRCA) shows strong expression of both
IGFBP2 and HSP27. B) Frequency distribution of expression of IGFBP2 and HSP27 during progression to
hormone-refractory prostate cancer as measured by immunohistochemistry on a prostate cancer tissue mi-
croarray.
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cluding several samples from different
sites of a tumor on each array. Further-
more, comparisons of the involvement of
one gene against another on the same ar-
ray or comparisons of one molecular al-
teration between two different stages of
tumor progression will generate relative
frequency estimates that are not biased by
the sampling method. Nevertheless, tissue
microarray technology should be re-
garded as a rapid, high-throughput tool to
survey many different genes and markers
to identify those that are most promising
for clinical applications. These would
then have to be tested on conventional
tissue specimens before clinical applica-
tion.
The tissue microarray results validated
that overexpression of IGFBP2 may be an
important event in hormone-refractory
prostate cancer, not only in the CWR22
xenograft model system but also in pa-
tients who had developed a recurrent tu-
mor during androgen deprivation therapy.
This finding is in agreement with recent
experimental and clinical studies (15–19)
indicating that the IGF system may be a
key growth regulatory pathway in pros-
tate cancer. IGFBP2 is a member of the
IGF growth factor system, which involves
two growth factors (IGF-I and IGF-II),
two IGF receptors (type I and II), seven
IGF-binding proteins (IGFBP1–7), as
well as IGFBP proteinases (16,20). IGF-I
stimulates growth and inhibits apoptosis
in normal and transformed epithelial cells
(21–24). High plasma levels of IGF-I
were recently shown to be associated with
increased risk of getting prostate cancer
(17). Moreover, IGF-I has been shown to
enhance androgen receptor-mediated
gene transcription in the prostate cancer
cell lines DU 145 (after cotransfection
with an androgen-inducible reporter gene
and an androgen receptor expression vec-
tor) and LNCaP in the absence of andro-
gen, suggesting that IGF-I may drive the
androgen-signaling pathway in hormone-
refractory prostate cancer (25). IGFBPs
can enhance or inhibit the bioactivity of
IGFs (IGF-I and IGF-II) by modulating
the availability of free IGFs for their re-
ceptors (26,27). IGFBP2 has also been
suggested to be an enhancer of IGF-I
function (22). It can be speculated that
overexpression of IGFBP2 promotes sur-
vival and androgen-independent growth
of prostate cancer by increasing the bio-
availability of IGFs. Members of the same
pathway (IGF-II and insulin receptor)
were also overexpressed in some of the
hormone-refractory xenograft tissues.
However, IGFBP2 was systematically
and most highly overexpressed, suggest-
ing that it may perhaps have a central role
in modulating the IGF signaling in hor-
mone-refractory prostate cancer. Alter-
ations of IGFBP2 may also play a role in
the development and progression of other
tumor types, such as breast, colorectal,
and ovarian cancers (28–30). Overexpres-
sion of IGFBP2 has also been observed in
cell lines established from several solid
tumors (31,32).
The overexpression of HSP27 in about
one third of hormone-refractory prostate
cancers but in only 5% of primary tumors
is intriguing in light of the fact that
HSP27 has been shown to increase resis-
tance to apoptosis induced by several
drugs such as doxorubicin (33–36).
Blockage of apoptosis may be an impor-
tant feature of hormone-refractory pros-
tate cancer and has been associated with
the differential expression of the Bcl-2
gene family (37–39). It was recently sug-
gested that HSP27 and Bcl-2 act at differ-
ent levels to prevent apoptosis in immor-
talized embryo fibroblasts, depending on
the type of apoptotic stimulus (40). The
role of HSP27 as a predictor of patient
outcome or response to therapy has re-
ceived attention in breast cancer (41–44),
but it has not been extensively studied in
prostate cancer. In one study (45), vari-
able HSP27 immunostaining was found in
13 prostate tumors derived from transure-
thral resection specimens, but no informa-
tion about the hormonal treatment status
was provided. Another study (46) did not
find HSP27 immunoreactivity in radical
prostatectomy specimens from patients
with clinically localized disease. On the
basis of this study, HSP27 expression is
unlikely to play a major role in primary
prostate cancer but may be important in
hormone therapy failure.
In summary, we describe a new strat-
egy based on the combination of cDNA
and tissue microarray technologies to ex-
plore the molecular basis of human pros-
tate cancer progression. Our results indi-
cate that multiple gene expression
changes may contribute to prostate cancer
progression and hormonal therapy failure
and that at least some of the mechanisms
involved in the CWR22 xenograft model
system may be similar to those contribut-
ing to therapy failure and hormone-
refractory prostate cancer growth in pa-
tients. We detected an association
between increased expression of IGFBP2
and HSP27 and the hormone therapy fail-
ure in both the xenograft model system
and in patients’ specimens. Further stud-
ies are needed to evaluate these molecules
as well as dozens of other differentially
expressed genes as diagnostic or thera-
peutic targets for hormone-refractory
prostate cancer.
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